Search clinical trials for: Cinacalcet HCl, Cinacalcet, Amgen (AMG) 073, Sensipar, Mimpara, Calcimimetic

Total 2019 results

Amgen

Completed

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease (BONAFIDE)

Secondary Hyperparathyroidism

United States, Italy, Belgium, Switzerland, Hungary, Spain, Turkey, Poland, Portugal, United Kingdom, Czech Republic, Macedonia, The Former Yugoslav Republic of
Amgen

Completed

Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects

Hyperparathyroidism
Amgen

Completed

12-month Study of AMG 073 in Renal Osteodystrophy

Renal Osteodystrophy
Amgen

Completed

Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism

Primary Hyperparathyroidism
Amgen

Completed

Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

End Stage Renal Disease
Amgen

Completed

E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events (EVOLVE)

Chronic Kidney Disease | Secondary Hyperparathyroidism
Amgen

Completed

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Hyperparathyroidism | Parathyroid Neoplasms
Amgen

Completed

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Secondary Hyperparathyroidism | Chronic Renal Insufficiency
Amgen

Completed

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

Safety, Tolerability, and Clinical Effects of Twice-daily Doses of Cinacalcet (AMG 073) in Adults With Primary Hyperparathyroidism (HPT)

Primary Hyperparathyroidism
Amgen

Completed

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

End Stage Renal Disease | Secondary Hyperparathyroidism
Amgen

Completed

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

End Stage Renal Disease
Amgen

Completed

A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)

Hyperparathyroidism, Primary
Amgen

Completed

A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Hyperparathyroidism, Primary
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Syndax Pharmaceuticals

Active, not recruiting

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Lymphoma | Refractory | Relapsed

United States
Chinese University of Hong Kong

Completed

Computer Aided Diagnosis in Upper GI Endoscopy (AIOGD)

Upper Gastrointestinal Disorder | OGD

Hong Kong
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

Psoriasis

New Zealand, Australia
Amgen

Completed

Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Belgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
Amgen

Terminated

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States, Korea, Republic of, Australia, Japan, Germany, Canada
Amgen

Completed

Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation

Kidney Transplantation
Amgen

Completed

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

Asthma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital; Amgen; H. Lee Moffitt...

Completed

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
Amgen

Completed

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Rectal Cancer | Colon Cancer
Amgen

Terminated

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Cutaneous Lupus | Lupus

United States, Australia, Canada
Amgen

Recruiting

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Spain, Australia, Germany, France, Japan
Amgen

Available

AMG 714 Expanded Access Program

Celiac Disease
Amgen

Completed

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

Glioblastoma or Malignant Glioma

United States, Australia, Netherlands, Germany, Spain, France
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Renal Impairment

United States
Amgen

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

Cardiovascular Disease

United States, Australia
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Chronic Migraine or Episodic Migraine

United States, Germany, Austria, Czechia, Canada, Denmark, Finland, Sweden
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Amgen

Recruiting

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (ROCKET-Outpost)

Atopic Dermatitis

United States
Amgen

Completed

AMG 529 First in Human Study

Cardiovascular

United States
Amgen

Terminated

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

Diabetes Mellitus

United States
Amgen

Completed

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

Systemic Lupus Erythematosus | Nephritis

United States, Hong Kong, France, Malaysia, Mexico
Amgen

Terminated

Single Ascending Dose Trial in Patients With Type 2 Diabetes

Diabetes Mellitus

United States
Amgen

Completed

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

Belgium, United States, Germany, Poland, United Kingdom, Lithuania
Amgen

Completed

Treatment for Patients With Osteoarthritis (OA)

Osteoarthritis
Amgen

Completed

Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease cGVHD

United States, Japan, France, Belgium
Bausch Health Americas, Inc.

Terminated

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

Psoriasis

United States, Germany, Poland, Switzerland, France, Canada
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

Elevated Serum Lipoprotein(a)

Hong Kong
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Hepatic Impairment

United States
Amgen

Completed

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

Type II Refractory Celiac Disease (RCD-II) | In-situ Small Bowel T-cell Lymphoma

Spain, United States, Finland, France, Netherlands
Amgen

Terminated

Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Amgen

Completed

Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581 (FIH)

Schizophrenia or Schizoaffective Disorder

United States

3

Subscribe